Clinical trials: Metastatic
Pancreatic Neoplasms, Pancreatic Cancer
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
This is a phase II study. It is designed to provide information about if high-dose ascorbate (vitamin C) increases survival for pancreatic cancer patients.
- Trial name
- PACMAN-II (NCT01515046)
- Testing
- Gemcitabine with escalating ascorbic acid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Joseph J. Cullen
Moderate to Severe Secondary Hyperparathyroidism, Stage 5 Chronic Kidney Diseases
A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients
To evaluate the effect of PTH lowering on erythropoietin consumption in calcitriol-resistant patients with stage 5 chronic kidney disease.
- Trial name
- NCT01506947
- Testing
- Paricalcitol, Darbepoetin alfa
- Volunteers
- 65 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Melanoma
MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma
This study is being done to evaluate the safety and the clinical activity of MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in patients with unresectable and progressive metastatic cutaneous melanoma.
- Trial name
- NCT00706238
- Testing
- GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A
- Where
- 6 sites in Argentina, Greece and 1 more
- Volunteers
- 5 people
- Sponsor
- GlaxoSmithKline
Metastatic HER2-Positive Breast Cancer
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
The purpose of this study is to see if a combination of drugs can help to treat breast cancer. This is a Phase II study which will test whether this combination of drugs is effective and will provide further information on side…
- Trial name
- NCT02252887
- Testing
- Gemcitabine, Trastuzumab, Pertuzumab
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
Enthuse M0 is a large phase III clinical trial studying the efficacy of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC).
- Trial name
- ENTHUSE M0 (NCT00626548)
- Testing
- ZD4054, Palcebo
- Where
- 322 sites in United States, Argentina and 37 more
- Volunteers
- 2,577 people
- Sponsor
- AstraZeneca
Cancer, Spinal Disease
Anderson Circulating Tumor Cell Burden (CTCB) Study
Phase 1 - Optimization Phase: Primary Objective: The primary objective of Phase 1 of this study is to determine the time point at which maximal Circulating Tumor Cell Burden (CTCB) occurs following standard vertebroplasty and…
- Conditions
- Cancer, Spinal Disease, Vertebral Compression Fractures
- Trial name
- NCT00819832
- Testing
- Kyphoplasty, Vertebroplasty, Cavity SpineWand
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Malignant Melanoma
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Background: Most therapeutic therapies for metastatic melanoma have focused on the ability of T-cell lymphocytes to kill cells of tumors.
- Conditions
- Melanoma, Malignant Melanoma, Melanoma, Experimental, Experimental Melanomas
- Trial name
- NCT00513604
- Testing
- aldesleukin, therapeutic autologous lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)
This is an observational follow-up study on the efficacy of 1st-line treatment with Herceptin (trastuzumab) in patients with metastatic breast cancer 7 years after initiation of treatment.
- Trial name
- NCT01332981
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Hoffmann-La Roche
Triple Negative Breast Neoplasms
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).
- Trial name
- IMpassion132 (NCT03371017)
- Testing
- Atezolizumab, Gemcitabine, Capecitabine
- Where
- 124 sites in United States, Argentina and 26 more
- Volunteers
- 595 people
- Sponsor
- Hoffmann-La Roche
Glaucoma, Glaucoma, Open-Angle
Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma
The goal of this study is to evaluate the efficacy and safety of the novel form of trans-scleral cyclophotocoagulation using micropulse diode laser and trans-pars plana treatment (Micropulse TSCPC, mTSCPC MP3, IRIDEX CYCLO G6™…
- Conditions
- Glaucoma, Glaucoma, Open-Angle, Glaucoma, Neovascular, Glaucoma and Ocular Hypertension
- Trial name
- NCT03187418
- Testing
- MicroPulse® P3 Glaucoma Device (MP3)
- Where
- Canada
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Low Vision, Age Related Macular Degeneration
Early Feasibility Study Using IOPCL MAG to Improve Near Vision in ARMD Subjects
This early feasibility study aims to improve near vision in subjects 55 years or older who have a clinical diagnosis of Age-Related Macular Degeneration.
- Trial name
- NCT04984590
- Testing
- IOPCL AMD MAG
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- OnPoint Vision Inc
Breast Cancer
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability.
- Trial name
- ABC (NCT00479674)
- Testing
- Abraxane, Bevacizumab, Carboplatin
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Duke University
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Colorectal Carcinoma
A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
The primary objective of this study is to investigate the safety and tolerability of the anti-vascular endothelial growth factor receptor-2 (anti-VEGFR-2) monoclonal antibody Ramucirumab (IMC-1121B) in combination with…
- Trial name
- NCT01286818
- Testing
- Ramucirumab (IMC-1121B), Irinotecan, levofolinate
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
Metastatic Leiomyosarcoma, Metastatic Liposarcoma
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
This phase I/II studies the side effects of avelumab and trabectedin and how well they work in treating patients with leiomyosarcoma or liposarcoma that has spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
- Trial name
- NCT03074318
- Testing
- Avelumab, Trabectedin
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Fred Hutchinson Cancer Center
Colorectal Cancer, Metastases
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine that panitumumab will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after…
- Trial name
- NCT00089635
- Testing
- Panitumumab
- Volunteers
- 203 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer
Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.
- Trial name
- NCT03003468
- Testing
- Imprime PGG, MK-3475
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Lawrence Feldman, MD
Liver Metastases, Recurrent Colon Cancer
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
RATIONALE: Drugs used in chemotherapy, such as floxuridine and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
- Trial name
- NCT00645710
- Testing
- gemcitabine hydrochloride, floxuridine, proteomic profiling
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Study of E7389 for Advanced or Metastatic Breast Cancer
The purpose of this study (E7389-J081-224; hereafter referred to as Study 224) is to evaluate the safety of patients who continue to receive E7389 after completing the Phase II clinical study (E7389-J081-221; hereafter referred…
- Trial name
- NCT00965523
- Testing
- Eribulin Mesylate
- Where
- 5 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Eisai Co., Ltd.
Colorectal Neoplasms
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy
To evaluate and compare the efficacy and safety of regorafenib versus placebo in subjects with colorectal cancer (CRC) after curative resection of liver metastasis and completion of all planned chemotherapy.
- Trial name
- COAST (NCT01939223)
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 121 sites in United States, Australia and 12 more
- Volunteers
- 25 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.